Member Info for goupplease

If it was a roll over I think they might have declared it at the time .
Monday morning will tell a story

What a change in 30 hours or so

That sort money I would say 002 deal done ?

I am 99% they are buys ,
It would have drooped if they were sells surely .
Interesting whom is buying .
Is that why they took it down yesterday ?

Feb 14 2020, 09:18 7.84 95,092 7.50 8.00 Buy £7,455.2128 O
Feb 14 2020, 09:17 7.555 15,187 7.50 8.00 Sell £1,147.37785 O
Feb 14 2020, 09:17 8.00 990,000 0.00 0.00 ? £79,200.0000 O
Feb 14 2020, 09:16 7.96 990,000 0.00 0.00 ? £78,804.0000 O
Feb 14 2020, 09:16 7.847 95,007 7.20 8.00 Buy £7,455.19929 O

Decent day , settle for that

Justified already
The seller's must be sore

Your will see some traders bale , their thirty percent up from yesterday

Going up with every trade .
7.22

7p

Buys 6.70

Mike Joseph
@benchpressmike
.
Check and foiiow

Nice only decent postal again

Many miles to travel yet , but a good day

Wonder how the new northern island minister will affect infa.
Grants or no grants .

Nfx have a significant rise with nothing changing ,
The mm have taken out the next tier of stops .
If the company could support the rise with positive news it will be flying again ,
Well done lth

How many will buy back higher than they sold ?
There was a lot of panic .
But it's still what we invested in only share holdings and bod have changed

We have got this far into Q1 ,
Recent events should not delay news too much .
If we had multiple offers on 002 they should have a partner by now .
Let's hope the next rns is a positive move

Completion of Ebers Strategic Cannabinoid Development agreement
001 completed

Waiting 002 Q1
Working on 004
You either sell or hold ...simple

Successful outcome of NXP001 pilot bioequivalence study

o NXP001 programme completed in accordance with Newsummit Biopharma agreement

o Additional out-licensing and development opportunities for NXP001 are currently under evaluation

· Completion of Ebers Strategic Cannabinoid Development agreement

o First patent filed from the collaboration and progress remains on track to deliver further milestones within the current financial year

· NXP002 progression towards clinic

o Partnerships in place to support development of NXP002 as an inhaled therapy for Idiopathic Pulmonary Fibrosis ("IPF") and IPF-induced cough

o Discussions with development partners commenced

o Assembling expert team to progress to patient studies

· Pipeline Update

o Continued growth of early-stage portfolio following discovery of new drug cocrystals with applications in fibrosis and oncology

o NXP004 entered into pipeline for a new indication with a high unmet need